|
- Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated
- Tarlatamab - Wikipedia
Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer [4] It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3
- FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY . . . - Amgen
IMDELLTRA™ (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy This indication is approved under accelerated approval based on overall response rate and duration of response
- FDA grants accelerated approval to tarlatamab-dlle for lung cancer
On May 16, 2024, the Food and Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc ) for extensive stage small cell lung cancer (ES-SCLC) with disease
- Dosing Administration | IMDELLTRA® (tarlatamab-dlle) HCP
IMDELLTRA ® (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy This indication is approved under accelerated approval based on overall response rate and duration of response
- Practical management of adverse events in patients receiving tarlatamab . . .
Tarlatamab is a bispecific T‐cell engager (BiTE) immunotherapy that binds both delta‐like ligand 3 (DLL3) on cancer cells and the cluster of differentiation 3 (CD3) molecule on T cells
- Tarlatamab-dlle - NCI - National Cancer Institute
Tarlatamab-dlle is approved to treat: Small cell lung cancer It is used in adults with extensive-stage cancer that got worse during or after treatment with platinum-based chemotherapy Tarlatamab-dlle is approved under FDA’s Accelerated Approval Program
- Tarlatamab Phase 3 Results: New SCLC Standard at ASCO 2025
Tarlatamab achieved a median overall survival (mOS) of 13 6 months compared to 8 3 months with chemotherapy The hazard ratio (HR) was 0 6, with a p-value less than 0 001, indicating statistical significance At 12 months from randomization, 62% of tarlatamab patients were alive, compared to 37% in the chemotherapy group
|
|
|